Athira Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

athira.com

Founded Year

2011

Stage

IPO | IPO

Total Raised

$116.02M

Date of IPO

9/18/2020

Market Cap

0.31B

Stock Price

8.93

About Athira Pharma

Athira Pharma (NASDAQ: ATHA) is a drug development company that strives to improve human health by advancing new therapies for neurodegenerative diseases, like Alzheimer's and Parkinson's. The company's approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.

Athira Pharma Headquarter Location

4000 Mason Road Suite 300

Seattle, Washington, 98195,

United States

206-221-8112

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Athira Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Athira Pharma is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Athira Pharma Patents

Athira Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Neurotrauma
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/1/2017

6/1/2021

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Grant

Application Date

6/1/2017

Grant Date

6/1/2021

Title

Related Topics

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Status

Grant

Latest Athira Pharma News

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 21, 2022

05/20/2022 | 09:01pm EDT Message : *Required fields Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 through June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. Click here to participate in this action. On June 17, 2021, after the markets closed, Athira announced that the company's board had placed its president and CEO, Leen Kawas, on temporary leave pending their investigation of "actions stemming from doctoral research Dr. Kawas conducted while at Washington State University." According to one investment analyst, the scientific basis for Athira came out of the work Kawas and her colleagues developed at Washington State and this news could have "clear negative implications for how we/investors view the asset, and/or management credibility." Healthcare news outlets also cited concerns that images in academic articles published by Kawas could have been manipulated. On this news, Athira's stock price fell $7.09 per share, or nearly 39%, to close at $11.15 per share on June 18, 2021, on unusually heavy trading volume. If you are a long-term stockholder of Athira, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com , by telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you. About Bragar Eagel & Squire, P.C. : Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005465/en/ © Business Wire 2022

Athira Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Athira Pharma Rank

  • When was Athira Pharma founded?

    Athira Pharma was founded in 2011.

  • Where is Athira Pharma's headquarters?

    Athira Pharma's headquarters is located at 4000 Mason Road, Seattle.

  • What is Athira Pharma's latest funding round?

    Athira Pharma's latest funding round is IPO.

  • How much did Athira Pharma raise?

    Athira Pharma raised a total of $116.02M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.